TCT recap: A Q&A with Gregg Stone

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

Gregg W. Stone, MD, co-director of the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, discussed the history of the 25-year-old event and its clinical trials with Cardiovascular Business in a two-part Q&A.

Part one, “From early tools to tablets,” is here. Part two, “Moving from anecdotal to evidence-based medicine,” is here.

Candace Stuart, Contributor

Related Content

Surgery outperforms PCI in NSTEMI patients with multivessel CAD
Boston Scientific enters IVL arms race with acquisition worth up to $664M
FDA sees value in no-implant heart failure device
Radial secondary access during TAVR limits complications
Medtronic’s Harmony TPVR system gains CE mark approval
History made: Young child treated with new heart device for very first time

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.